IHH HEALTHCARE BERHAD (5225.KL)

About IHH HEALTHCARE BERHAD

Company Description

IHH Healthcare Berhad is an investment holding company and one of the world's leading listed healthcare operators, providing healthcare services across 10 countries. Operating over 80 hospitals, its key markets are Malaysia, Singapore, Turkey/Europe (via Acibadem), and India. The group focuses on private healthcare, leveraging specialized centres such as cancer care at Pantai Hospital Kuala Lumpur and renal transplants at Prince Court Medical Centre. It is listed on Bursa Malaysia and included in the FTSE4Good Bursa Malaysia Index.

Business Model

IHH generates revenue from inpatient and outpatient services, specialized medical care, and laboratory services. The business model emphasizes high-acuity and complex case-mix treatments to drive revenue intensity. It is pivoting towards day-care procedures and ambulatory care centres to enhance operational efficiency and margins, freeing up overnight beds for critical cases. Revenue is supported by medical tourism and domestic demand, with cost management achieved through group-wide centralized procurement. The model also relies on strategic acquisitions and integration synergies, such as the Fortis-Gleneagles O&M collaboration in India.

Revenue Segment

Revenue is generated primarily from hospital operations, laboratory services, and hospital management. In FY25, daycare revenue in Malaysia grew approximately 10% YoY to RM550m. Medical tourism revenue in Malaysia reached RM724m, accounting for 15% of Malaysia's total revenue. Group revenue for FY25 was RM25,745m. Specific percentage breakdowns by service segment for the whole group are not detailed, but the focus is on clinical services, with non-Lira paying patients contributing significantly to Turkey's revenue.

Geographic Segment

For FY25, total revenue was RM25,745m. Malaysia contributed RM4,825m (approx. 18.7%). For the Acibadem segment (Turkey and Europe), FY25 revenue breakdown comprised Domestic patients 63%, European patients 23%, and Foreign patients 14%. Other key markets include Singapore and India; Singapore contributed 30% of FY25 group EBITDA. The group also has operations in Greater China.

Top Client

The reports do not name specific corporate or individual clients. The customer base consists of private patients, including domestic users, medical tourists, and high-net-worth individuals. In Turkey, Acibadem serves wealthy tier-1 domestic patients holding USD/EUR assets and USD-paying European patients. In Malaysia, medical tourists are a significant customer group, while in Singapore, patients utilize high-end treatments like proton therapy.

Operational Scale

As of December 2025, IHH operated 12,785.8 licensed beds across its global network. The group operates over 80 hospitals in 10 countries. In India, the combined Fortis-Gleneagles network manages over 6,000 beds across 11 states. The workforce exceeds 65,000 employees. Future capacity targets include adding 4,000 additional beds across the group by FY2030.

Associate Companies

Fortis Healthcare (31.17% ownership). ParkwayLife REIT (32.91% ownership). Acibadem Healthcare is a 90%-owned subsidiary. The group holds stakes in various joint ventures and associates, which contributed RM32m to pre-tax profit in FY25. Ownership percentages mentioned include 35.58% (CGS) or 32.91% (HLIB) for ParkwayLife REIT and 31.10% (CGS) or 31.17% (HLIB/MBIB) for Fortis Healthcare.

Latest IHH HEALTHCARE BERHAD news

• Maybank Says Potential MSCI Downgrade of Indonesia Could Benefit Malaysian Stocks, Especially Banks
• Malaysian Stocks Face a Valuation Squeeze as Bond Yields Rise; MBSB Looks to Budget 2027 for Support
• Kenanga Upgrades IHH After Investor Meeting as Singapore Recovery and China Turnaround Gain Momentum
• One of Best Healthcare Analysts Upgrades IHH to Buy After 2Q Earnings Beat, Says Singapore Concerns Are Largely Priced In
• Hong Leong Downgrades Malaysia Healthcare Sector as IPO-Led Re-Rating Runs Its Course